Papers Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7416.643 (Published 18 September 2003) Cite this as: BMJ 2003;327:643 Article Related content Metrics Responses Peer review Related articles This Week In The BMJ Adding methylxanthines to standard COPD treatment is not beneficial Published: 18 September 2003; BMJ 327 doi:10.1136/bmj.327.7416.0-d Cited by... Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive SummaryFulltext PDF The use of Ipratropium and Tiotropium as novel agents to reduce inflammation in in vitro macrophage modelsFulltext PDF Abstract Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive SummaryFulltext PDF Abstract Drugs (including oxygen) in severe COPDFulltext PDF Abstract Beyond the "ABC approach"Fulltext PDF Abstract Management of acute ventilatory failure.Fulltext PDF Abstract COPD exacerbations {middle dot} 5: Management.Fulltext PDF Abstract Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trialFulltext PDF Abstract Aminophylline for COPD exacerbations? Not usuallyFulltext PDF Abstract COPD: current therapeutic interventions and future approachesFulltext PDF Abstract Chronic obstructive pulmonary disease: the clinical management of an acute exacerbationFulltext PDF Abstract Review: methylxanthines are not effective for acute exacerbations of chronic obstructive pulmonary diseaseFulltext PDF Abstract Methylxanthines Offer No Benefit in Acute COPD ExacerbationsFulltext PDF Abstract
